missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Human Perilipin-3 Antibody, R&D Systems™

Mouse Monoclonal Antibody
Brand: R&D Systems MAB76641
This item is not returnable.
View return policy
Description
Perilipin-3/TIP47 Monoclonal specifically detects Perilipin-3/TIP47 in Human samples. It is validated for Western Blot, Immunohistochemistry.
Specifications
| Perilipin-3/TIP47 | |
| Monoclonal | |
| LYOPH | |
| Western Blot 0.25 ug/mL, Immunohistochemistry 8-25 ug/mL | |
| O60664 | |
| PLIN3 | |
| E. coli-derived recombinant human Perilipin-3 Met1-Lys434 Accession # O60664 | |
| 100 μg | |
| Primary | |
| Detects human Perilipin-3 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) Perilipin-2 or rhPerilipin-5 is observed. | |
| Human | |
| Purified |
| Western Blot, Immunohistochemistry | |
| 779103 | |
| Unconjugated | |
| Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
| Cargo selection protein TIP47, M6PRBP1, M6PRBP1MGC2012, Mannose-6-phosphate receptor-binding protein 1, perilipin 3,47 kDa MPR-binding protein, perilipin-3, Perilipin3, Placental protein 17,47 kDa mannose 6-phosphate receptor-binding protein, PLIN3, PP17, PP17MGC11117, tail-interacting protein, 47 kD, TIP47, TIP47mannose-6-phosphate receptor binding protein 1 | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| 10226 | |
| Sterile PBS to a final concentration of 0.5 mg/mL. | |
| Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
| IgG2b |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction